CENTENE Q1 FY26 earnings call CNC

Centene reported Q1 adjusted diluted EPS of $3.37, just under $0.50 better than expectations, on $44.7 billion of premium and service revenue and a consolidated HBR of 87.3%. The beat was largely driven by outperformance in Medicaid and Medicare segment HBRs. Management raised full-year 2026 adjusted EPS guidance to greater than $3.40 from greater than $3.00, added $1 billion of premium revenue (largely Texas Medicaid), lowered the SG&A guidance range 10 bps, added $50 million to investment income, and left the full-year HBR range unchanged at 90.9%-91.7%. Management repeatedly framed the raise as prudent given it is early in the year.

Medicaid HBR of 93.1% improved 50 bps versus Q1 2025 and marked the third consecutive quarter of margin progress. Outperformance came partly from a lighter-than-forecast flu season and a slight weather-related utilization benefit, but management stressed fundamental gains from a multi-pronged trend program (utilization management standardization, clinical programs, network optimization, payment integrity and fraud/waste/abuse). Behavioral health remains the largest trend driver, with home health and high-cost drugs consistent contributors, though management is beginning to see pockets of deceleration (notably units-per-utilizer in behavioral health and stabilizing year-over-year ABA trends). The full-year assumes composite rate yield ~4.5% against net trend in the mid-4% range.

The Medicare segment posted an 84.9% HBR, better than forecast, with both MA and PDP contributing. In MA, membership is being aligned with the Medicaid footprint; D-SNP (transcribed 'decent') membership is now 40% of the portfolio, with stronger year-over-year retention and a more favorable mix after strong AEP/OEP execution. Value-based care contracts have been simplified and focused, with total-cost-of-care models targeting oncology, chronic kidney disease and behavioral health. PDP ended the quarter with just over 8.7 million members (~$25B of segment revenue); outperformance was driven by slightly lower-than-assumed specialty drug trend. Finalized 2027 MA rates improved versus the advanced notice but remain below trend; management maintains a path to 2027 breakeven.

Marketplace ended Q1 with 3.58 million members (metal mix: just under half Silver, ~35% Bronze, remainder Gold), expected to attrit to a little over 3 million by year-end. Pretax earnings were on track: a slightly higher-than-expected HBR was offset by SG&A favorability. The higher HBR was isolated in Silver-tier members whose gross medical costs ran above forecast before risk adjustment. New end-of-March Wakely data — an industry-wide early-data collaboration Centene initiated with peers — confirmed post-APTC market contraction, a Silver-to-Bronze/Gold shift, and that Ambetter retained higher-acuity Silver members likely due a meaningful risk-adjustment receivable. Management moved to forecasting a slight year-end risk-transfer receivable (versus a prior payable) but did not book the full suggested offset, cutting Marketplace pretax margin guidance to ~3% from ~4% pending June Wakely data.

Centene ended Q1 with $437 million of cash available for general corporate use and generated $4.4 billion of operating cash flow, aided by strong earnings and a partial sale of its 2025 CMS PDP receivable. The company sold $1 billion of standalone 2025 Part D risk-share receivables and used the proceeds to repurchase $1 billion of senior notes, cutting the debt-to-cap ratio to 43.2% from 46.5% at year-end. Medical claims liability was $20.6 billion (48 days in claims payable, up 2 days from Q4 2025). Management flagged upcoming maturities (~$1.2B due December 2027, ~$2.3B in 2028) that it expects to refinance about a year out, with the ability to sell more of the 2025 receivable.

Management devoted significant attention to fraud, waste and abuse in Medicaid — leveraging 30 states of aggregated data to identify outlier providers, and advocating for CMS reforms (proactive payment suspensions, safe harbors, two-way data sharing) in response to a CMS RFI. On work requirements under OB3, Nebraska begins earlier than others; management sees CMS guidance on rate certification (accounting for acuity shifts, mid-year rates and retros) as helpful, and views the 2027/2028 risk-pool impact as manageable given a smaller, more focused affected population. Industry-wide prior-authorization commitments were expanded last week to make the process faster, easier and less expensive. A shortened open enrollment period applies for 2027, and certain stayed Marketplace program-integrity measures may roll into 2027 pending a court case expected to resolve around summer.